Ursodeoxycholic Acid Drug Product Market Analysis By Type (Tablet, Capsule), By Indication (Gallstones, Hepatopathy, Biliary Disease, Primary Biliary Cholangitis (PBC), Other Indications), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: Feb 2024
Report ID: 14703
Number of Pages: 201
Format:

Fact Checked

Cite this Research

- 1. Ursodeoxycholic Acid Drug Product Market Introduction
  - 1.1. Definition
  - 1.2. Taxonomy
  - 1.3. Research Scope
- 2. Executive Summary
  - 2.1. Key Findings by Major Segments
  - 2.2. Top strategies by Major Players
- 3. Global Ursodeoxycholic Acid Drug Product Market Overview
  - 3.1. Ursodeoxycholic Acid Drug Product Market Dynamics
    
    3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges
  - 3.2. PESTLE Analysis
  - 3.3. Opportunity Map Analysis
  - 3.4. PORTER'S Five Forces Analysis
  - 3.5. Market Competition Scenario Analysis
  - 3.6. Product Life Cycle Analysis
  - 3.7. Opportunity Orbits
  - 3.8. Manufacturer Intensity Map
- 4. Global Ursodeoxycholic Acid Drug Product Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
  - 4.1. Global Ursodeoxycholic Acid Drug Product Market Analysis by Type: Introduction
  - 4.2. Market Size and Forecast by Region
  - 4.3. Capsule
  - 4.4. Tablet
- 5. Global Ursodeoxycholic Acid Drug Product Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
  - 5.1. Global Ursodeoxycholic Acid Drug Product Market Analysis by Application: Introduction
  - 5.2. Market Size and Forecast by Region
  - 5.3. Gallstone
  - 5.4. Hepatopathy
  - 5.5. Biliary Disease
  - 5.6. Other
- 6. Global Ursodeoxycholic Acid Drug Product Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
  - 6.1. North America
    
    6.1.1. North America Ursodeoxycholic Acid Drug Product Market: Regional Trend Analysis
    
    6.1.1.1. US
    
    6.1.1.2. Canada
    
    6.1.1.3. Mexico
  - 6.2.1. Europe
    
    6.2.1. Europe Ursodeoxycholic Acid Drug Product Market: Regional Trend Analysis
    
    6.2.1.1. Germany
    
    6.2.1.2. France
    
    6.2.1.3. UK
    
    6.2.1.4. Russia
    
    6.2.1.5. Italy
    
    6.2.1.6. Spain
    
    6.2.1.7. Rest of Europe
  - 6.3. Asia-Pacific
    
    6.3.1. Asia-Pacific Ursodeoxycholic Acid Drug Product Market: Regional Trend Analysis
    
    6.3.1.1. China
    
    6.3.1.2. Japan
    
    6.3.1.3. Korea
    
    6.3.1.4. India
    
    6.3.1.5. Rest of Asia
  - 6.4. Latin America
    
    6.4.1. Latin America Ursodeoxycholic Acid Drug Product Market: Regional Trend Analysis
    
    6.4.1.1. Brazil
    
    6.4.1.2. Argentina
    
    6.4.1.3. Rest of Latin America
  - 6.5. Middle East and Africa
    
    6.5.1. Middle East and Africa Ursodeoxycholic Acid Drug Product Market: Regional Trend Analysis
    
    6.5.1.1. GCC
    
    6.5.1.2. South Africa
    
    6.5.1.3. Israel
    
    6.5.1.4. Rest of MEA
- 7. Global Ursodeoxycholic Acid Drug Product Market Competitive Landscape, Market Share Analysis, and Company Profiles
  - 7.1. Market Share Analysis
  - 7.2. Company Profiles
  - 7.3. Dr. Falk Pharma
    
    7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments
  - 7.4. Daewoong Pharmaceutical
    
    7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments
  - 7.5. Teva
    
    7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments
  - 7.6. Epic Pharma
    
    7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments
  - 7.7. Mitsubishi Tanabe Pharma
    
    7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments
  - 7.8. Lannett
    
    7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments
  - 7.9. Mylan
    
    7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments
  - 7.10. Bruschettini
    
    7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments
  - 7.11. Impax
    
    7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments
  - 7.12. Shanghai Pharma
    
    7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments
  - 7.13. Grindeks
    
    7.13.1. Company Overview
    
    7.13.2. Financial Highlights
    
    7.13.3. Product Portfolio
    
    7.13.4. SWOT Analysis
    
    7.13.5. Key Strategies and Developments
- 8. Assumptions and Acronyms
- 9. Research Methodology
- 10. Contact
- Dr. Falk Pharma
- Daewoong Pharmaceutical
- Teva Pharmaceuticals
- Epic Pharma
- Mitsubishi Tanabe Pharma
- Sun Pharmaceutical Industries Ltd.
- ICE s.p.a.
- Merck Kga
- Dipharma Francis Srl
- Axplora